Literature DB >> 11504478

Telomerase targeting in cancer treatment: new developments.

Marco N. Helder1, Steven de Jong, Elisabeth G. E. de Vries, Ate G. J. van der Zee.   

Abstract

Telomerase, a ribonucleoprotein expressed in 85% of advanced cancers but not in most somatic cells, compensates for telomeric DNA erosion and as such stabilizes cell immortality. Telomerase inhibition might restore mortality in tumor cells. Recent progress is illustrated in studies on telomerase and telomere targeting with differentiation induction, reverse transcriptase inhibitors, promoter down regulation, antisense inhibition, and blockage of telomere/telomerase interactions. Also, new developments are described indicating that anti-telomerase treatment can induce apoptosis in tumor cells and can chemosensitize drug-resistant cell lines. Implications of these findings for anti-telomerase-based therapeutic applications, in particular in combination therapies, are discussed. Copyright 1999 Harcourt Publishers Ltd.

Entities:  

Year:  1999        PMID: 11504478     DOI: 10.1054/drup.1999.0074

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  4 in total

Review 1.  Natural and pharmacological regulation of telomerase.

Authors:  Jean-Louis Mergny; Jean-François Riou; Patrick Mailliet; Marie-Paule Teulade-Fichou; Eric Gilson
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

2.  Telomerase activity as a tumor marker in Indian women with cervical intraepithelial neoplasia and cervical cancer.

Authors:  Alpana Sharma; Medha Rajappa; Alpana Saxena; Manoj Sharma
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

3.  Antitumor mechanism of antisense cantide targeting human telomerase reverse transcriptase.

Authors:  Qing-You Du; Xiao-Bo Wang; Xue-Jun Chen; Wei Zheng; Sheng-Qi Wang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

4.  Construction of a novel vector expressing the fusion suicide gene yCDglyTK and hTERT-shRNA and its antitumor effects.

Authors:  Jia Li; Guiying Zhang; Ting Liu; Huan Gu; Lu Yan; Bolin Chen
Journal:  Exp Ther Med       Date:  2012-06-18       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.